Novartis Says Accord Can't Make, Sell Generic Bone Drug

Law360, Los Angeles (November 27, 2013, 4:34 PM EST) -- Novartis Pharmaceuticals Corp. hit Accord Healthcare Inc. with a patent infringement lawsuit in New Jersey federal court on Tuesday, saying Accord asked the U.S. Food and Drug Administration to approve generic versions of Novartis’ bone drug Zometa prior to the expiration of a patent that protects it.

Novartis seeks to enforce its rights to Zometa, which was first approved by the FDA in 2001 and is approved to treat hypercalcemia of malignancy, a condition resulting in high calcium blood levels due to cancer, multiple myeloma and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.